A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study

William J Gradishar*, Nicholas J. Vogelzang, Lary J. Kilton, Steven J. Leibach, Alfred W Rademaker, Suzanne French, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

Original languageEnglish (US)
Pages (from-to)171-174
Number of pages4
JournalInvestigational New Drugs
Volume13
Issue number2
DOIs
StatePublished - Jun 1 1995

Fingerprint

Echinomycin
Phase II Clinical Trials
Sarcoma
Quinoxalines
Neoplasms
Cyclic Peptides
Nausea
Vomiting
Appointments and Schedules
Anti-Bacterial Agents
Therapeutics

Keywords

  • echinomycin
  • metastatic
  • sarcoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{eb5de591dc734c07a35dda2761efc91c,
title = "A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study",
abstract = "Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.",
keywords = "echinomycin, metastatic, sarcoma",
author = "Gradishar, {William J} and Vogelzang, {Nicholas J.} and Kilton, {Lary J.} and Leibach, {Steven J.} and Rademaker, {Alfred W} and Suzanne French and {Benson III}, {Al B}",
year = "1995",
month = "6",
day = "1",
doi = "10.1007/BF00872868",
language = "English (US)",
volume = "13",
pages = "171--174",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study. / Gradishar, William J; Vogelzang, Nicholas J.; Kilton, Lary J.; Leibach, Steven J.; Rademaker, Alfred W; French, Suzanne; Benson III, Al B.

In: Investigational New Drugs, Vol. 13, No. 2, 01.06.1995, p. 171-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study

AU - Gradishar, William J

AU - Vogelzang, Nicholas J.

AU - Kilton, Lary J.

AU - Leibach, Steven J.

AU - Rademaker, Alfred W

AU - French, Suzanne

AU - Benson III, Al B

PY - 1995/6/1

Y1 - 1995/6/1

N2 - Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

AB - Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

KW - echinomycin

KW - metastatic

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0028844387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028844387&partnerID=8YFLogxK

U2 - 10.1007/BF00872868

DO - 10.1007/BF00872868

M3 - Article

C2 - 8617582

AN - SCOPUS:0028844387

VL - 13

SP - 171

EP - 174

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -